Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Àêóøåðñòâî è ãèíåêîëîãèÿ > Èíôåêöèè ïîëîâûõ ïóòåé è âîñïàëèòåëüíûå çàáîëåâàíèÿ

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #46  
Ñòàðûé 05.09.2003, 22:28
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Talking Òàê Âû è ìèêðîáèîëîãîì ïîäðàáàòûâàëè, Âëàäìèð ßêîâëåâè÷?

âñåâîçìîæíûå áàê. ïîñåâû ëè÷íî ÿ, â îòëè÷èå îò Âàñ, äåëàë äîñòàòî÷íî ìíîãî.
Íå ïðàâäà Âàøà ìîé âå÷íûé îïïîíåò. ß â íåäåëþ çàñåâàþ Uricult' îâ áîëüøå ÷åì íåêîòîðûå ìèêðîáèîëîãè, ýòî 100%. Íî ÿ æå íå ïðåòåíäóþ â ñïåöèàëèñòû ïî êóëüòèâèðîâàíèþ óðåàïëàçì è íå ñ÷èòàþ ñåáÿ ìèêðîáèîëîãîì (êàê íå äîëæåí ñåáÿ ñ÷èòàòü ãèíåêîëîãîì òîò ìóæèê èç ïîãîâîðêè). Êñòàòè, ìíîãèå íàøè ëàáîðàòîðèè óòâåðæäàþò, ÷òî âûïîëíÿþò äîñòîâåðíûå ïîñåâû õëàìèäèé íà êëåòî÷íûå êóëüòóðû. Âû â ýòî òîæå âåðèòå, ýêñïåðò âî âñåõ "ìåõàíèçìàõ" Âû íàø?
Îòâåòèòü ñ öèòèðîâàíèåì
  #47  
Ñòàðûé 05.09.2003, 23:17
V. ZAITSEV V. ZAITSEV âíå ôîðóìà Ïîë ìóæñêîé
çàáàíåí
      
 
Ðåãèñòðàöèÿ: 25.07.2001
Ñîîáùåíèé: 3,330
V. ZAITSEV
Îé, Àëåêñåé Âèêòîðîâè÷!
Êîãäà ÿ ïðîáîâàë íà ôîðóìå ïðèâîäèòü êîå–êàêèå ìàòåìàòè÷åñêèå âûêëàäêè, êàñàþùèåñÿ ìàò. ñòàòèñòèêè, ïðè÷åì íà ýëåìåíòàðíîì óðîâíå, òàê è ÷óâñòâîâàëîñü, êàê ãëóáîêî ïðèâåðæåíöû «äîêàçàòåëüíîé ìåäèöèíû» çåâàþò.
À óæ î áàê. ëàáîðàòîðèÿõ! Âàñ ïîïðîñèëè íàçâàòü êîíêðåòíûå ëàá., à Âû îá àíàëèçàõ íà óðåàïëàçìó 10 ëåòíåé äàâíîñòè! Âû õîòü ïðèìåðíî ïðåäñòàâëÿåòå, ÷òî èç ñåáÿ òàêèå áóëüîíû ïðåäñòàâëÿþò è ÷åì îòëè÷àþòñÿ? À ñêîëüêî ñåé÷àñ ñòîÿò ñòàíäàðòíûå ñðåäû, õîòÿ áû BioMerieux (Ôðàíöèÿ)? Âû õîòü ðàç â âûðàùåííûå êîëîíèè òåõ æå ìèêîïëàçì è óðåàïëàçì â ìèêðîñêîï âèäåëè? Êàê îíè âûãëÿäÿò, ÷åì îòëè÷àþòñÿ?
Àëåêñåé Âèêòîðîâè÷! Åñëè Âû íà ýòîì ôîðóìå ãëàâíûé ñïåöèàëèñò ïî ýñòðàäå, òî ýòî íå îçíà÷àåò, ÷òî è âî âñåõ îñòàëüíûõ îáëàñòÿõ.
Ëàäíî, Àëåêñåé Âèêòîðîâè÷, bye. Ìåíÿ äâå íåäåëè â Ìîñêâå íå áóäåò.
Îòâåòèòü ñ öèòèðîâàíèåì
  #48  
Ñòàðûé 06.09.2003, 07:32
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âëàäèìèð ßêîâëåâè÷,
Èçáàâüòå ìåíÿ ïîæàëóéñòà îò îïèñàíèé èç ÷åãî ñîñòîÿò ñðåäû äëÿ âûðàùèâàíèÿ ìèêîïëàçì è ïð. Êñòàòè, â ïîñëåäíåì è íåîäíîêðàòíî öèòèðîâàííîì ìíîé àòëàñå ïî STD îò S. Morse et al. (2003) ãîâîðèòñÿ, ÷òî êîììåð÷åñêè äîñòóïíûå ñðåäû òèïà BioMerieux, ðåàãèðóþùèå íà íàëè÷èå ìèêðîîãðàíèçìà èçìåíåíèåì öâåòà ìåíåå ñïåöèôè÷íû è ÷óâñòâèòåëüíû ïî ñðàâíåíèþ ñî ñðåäàìè, êîòîðûå èçãîòàâëèâàþòñÿ â ñïåöèàëèçèðîâàííûõ ëàáîðàòîðèÿõ. ×òî äî ìåíÿ, òî ìíå íåò ñìûñëà ñìîòðåòü â äàííîì ñëó÷àå â êíèãó è âèäåòü èçâåñòíóþ êîìáèíàöèþ. ß ñìîòðþ â öèñòîñêîï è ïð., ìîè êîëëåãè ìèêðîáèîëîãè (ïîâåðüòå î÷åíü ãðàìîòíûå ëþäè) ñìîòðÿò â ìèêðîñêîï è äàþò àäåêâàòíûå îöåíêè ñåãîäíÿøíåìó ñîñòîÿíèþ äåë â èõ îáëàñòè. Êàæäûé äåëàåò ñâîå äåëî. Íó à òà èíôîðìàöèÿ î ëàáîðàòîðèÿõ Ìîñêâû è Ïèòåðà, êîòîðîé ÿ ðàñïîëàãàþ âïîëíå ñîîòâåñòâóåò îáùåìó ñîñòîÿíèþ äåë â íàøåé ìåäèöèíå. Ïî äðóãîìó âåäü è áûòü íå ìîæåò, ÷óäåñ íå áûâàåò. Ðàçâå ÷òî â ñôåðå îçîíîâåäåíèÿ, ñâîáîäíîé îò îáúåêòèâíîé ðåàëüíîñòè. Õîðîøåãî Âàì îòäûõà, Âëàäèìèð ßêîâëåâè÷. Ìîæåò ïðèõâàòèòå ñ ñîáîé êíèæêó Ð. Ôëåò÷åð Êëèíè÷åñêàÿ ýïèäåìèîëîãèÿ. Ìîæåò ÷òî è ïåðåêëèêíåò òîãäà â âàøåì îçîíîâîì âçãÿäå íà ñåãîäíÿøíþþ ìåäèöèíó. Íå îáèæàéòåñü!
Îòâåòèòü ñ öèòèðîâàíèåì
  #49  
Ñòàðûé 08.09.2003, 02:53
Tashaia Tashaia âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 07.09.2003
Ãîðîä: Rostov
Ñîîáùåíèé: 3
Tashaia *
Çäðàâñòâóéòå, åùå ðàç îá óðåàïëàçìîçå...õîòåëîñü áû ïîëó÷èòü íåçàâèñèìîå ìíåíèå ïî ìîåé ñèòóàöèè!!!!
Îáðàòèëàñü ê âðà÷ó ïî ïîâîäó çóäà è âûäåëíèé (íå êðîâÿíèñòûå).
Ïîñëå îñìîòðà âðà÷ ñîîáùèëà,÷òî âûäåëåíèÿ äåéñòâèòåëüíî íåõðîøèå, íàáëþäàåòñÿ ýðîçèÿ
øåéêè ìàòêè, êîòîðàÿ ïðè ââåäåíèè çåðêàë çàêðîâîòî÷èëà, è ÷òî ñóäÿ ïî âñåìó ó ìåíÿ äàâíåå
õðîíè÷åñêîå âîñïàëåíèå.
Ðàíåå áîëåçíåííûõ îùóùåíèé ÿ íå èñïûòûâàëà,òîëüêî î÷åíü ðåäêî ïðè ìåíñòðóàöèÿõ, íå áåðåìåííà,
íå ðîæàëà, àáîðòîâ íå äåëàëà, ïðèìåíÿþ Ìåðñèëîí.
Óçè ïàòîëîãèé íå ïîêàçàëî.
Ïî ðåçóëüòàòàì ÏÖÐ ïîòàâëåí äèàãíîç óðåàïëàçìîç è íàçíà÷åíî ëå÷åíèå, ïåðâûé êóðñ êîòîðîãî
ñëåäóþùèé:
1) äëÿ îáîèõ ïàðòíåðîâ: öèêëîôåðîí 2,0 â/ì ÷åðåç äåíü - 10 äí,Ö-êîìïëåêñ 1òõ2ð - 10äí,
áèíîêëàä 250ìãõ2ð - 10äí,ñóìàìåä 500ìãõ1ð - 3äí, áèîðèôäèí 1êõ2ð - 10äí,
Ýññåíöèàëèÿ 1êõ2ð - 10äí
2)ìåñòíî ìíå: êëîðèòìàçîë óòðîì - 10äí, áåòàäèí íà íî÷ü - 10äí
ìåñòíî ïàðòíåðó: õëîðãåêñèäèí õ 2ð - 10-20äí
3)òîëüêî äëÿ ìåíÿ âìåñòå ñ 1) è 2): äèêëîôåíàê 3,0 â/ì - 5äí, ìàãíåçèÿ 25% 5,0 íà íîâîê.05% - 10 äí
äèêëîïàò ñâ â ïð.êèøêó - 10äí.
Î âòîðîì êóðñå ïîêà íè÷åãî òî÷íîãî íå ãîâîðèëîñü.

Õîòåëîñü áû óçíàòü Âàøå ìíåíèå, îñîáåííî î íàçíà÷åííîì êóðñå ëå÷åíèÿ, íàñêîëüêî îïðàâäàíî
òàêîå êîëè÷åñòâî ëåêàðñòâ, íå ÷ðåâàòî ëè êàêèìè-ëèáî ïîñëåäñòâèÿìè äëÿ çäîðîâüÿ.
À òàêæå ìîæåò ëè ÏÖÐ ïîêàçàòü äðóãèå âîçáóäèòåòåëè (íàïðèìåð êàíäèä è ò.ï.), ò.ê. êðîìå ÏÖÐ
äðóãèå àíàëèçû ó ìåíÿ íå áðàëèñü.

Çàðàíåå âñåì áëàãîäàðíà, Íàòàëüÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #50  
Ñòàðûé 08.09.2003, 06:56
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íàòàøà,
ß íà âàø âîïðîñ óæå îòâåòèë íà ôîðóìå íàøåé êëèíèêè. Òî, ÷òî ÿ âàì íàïèñàë ñîîòâåñòâóåò ñòàíäàðòó ëå÷åíèÿ óðåàïëàçìîçà, ïðèíÿòîìó âî âñåì öèâèëèçîâàííîì ìèðå. È åñëè ó Âàñ äåéñòâèòåëüíî óðåàïëàçìîç, åãî íàäî ëå÷èòü èìåííî êàê ÿ âàì óæå ïèñàë. ×èòî êàñàåòñÿ ÏÖÐ, òî ýòèì ìåòîäîì ìîæíî âûïîëíÿòü èññëåäîâàíèÿ è íà êàíäèäû,\ è äð. èíôåêöèè. Îäíàêî íå äëÿ âñåõ èíôåêöèé ÏÖÐ ÿâëÿåòñÿ ìåòîäîì âûáîðà. Îí, â ÷àñòíîñòè, íå ïîçâîëÿåò óñòàíîâèòü ÷óâñòâèòåëüíîñòü èíôåêöèé ê àíòèáèîòèêàì. Õîòÿ â ñëó÷àÿ ñ èíôåêöèÿìè, ïåðåäàâàåìûìè ïîëîâûì ïóòåì (ÈÏÏÏ), èõ ÷óâòâèòåëüíîñòü ê àíòèáèîòèêàì ðóòèííî íå îïðåäåëÿåòñÿ, ò.ê. ïîêà åùå ìàëî øòàìîâ ÈÏÏÏ, óñòîé÷èâûõ ê ñòàíäàðòíûì ïðåïàðàòàì.

Òî, ÷òî Âàì íàçíà÷èëè â Ðîñòîâå íà Äîíó äîñòîéíî ïîìåùåíèÿ â ðàçäåë ôîðóìà î ìåäèöèíñêîì øàðëàòàíñòâå. Äà, åùå äîáàâëþ. Íå â êîåì ñëó÷àå íå ïðèìåíÿéòå ïàðòíåðó "ìåñòíî õëîðãåêñèäèí". Ìîæíî âûçâàòü õèìè÷åñêèé îæîã óðåòðû è åå ñóæåíèå (ñòðèêòóðó). Õîòÿ ìîé êîëëåãà èç Âàøåãî ãîðîäà ïðîô. Ì.È. Êîãàí ïðåêðàñíî îïåðèðóåò ñòðèêòóðû óðåòðû, íî âñå æå ëó÷øå îáîéòèñü áåç ýòîãî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #51  
Ñòàðûé 08.09.2003, 10:52
mina mina âíå ôîðóìà
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.03.2003
Ñîîáùåíèé: 82
mina *
Íàòàøà! Ãäå â ðîñòîâå âû ëå÷èòåñü? ß òîæå èç ðîñòîâà, ëå÷èëà ýòó óðåàïëàçìó óæå ñíà÷àëà ôðîìèëèäîì, òåïåðü ñóìàìåäîì (5 äíåé) è îôëîêñàöèíîì 10 äíåé, ñäàëà êîíòðîëü è îïÿòü íå ïîìîãëî, ñåé÷àñ òîæå êîëþ öèêëîôåðîí.
Äîêñèöèêëèí íå ìîãó ïèòü èç-çà ïå÷åíè, è òåïåðü äóìàþ - ÷åì æå åùå ìîæíî åå ëå÷èòü? Íå âñå òàê ïðîñòî....
Îòâåòèòü ñ öèòèðîâàíèåì
  #52  
Ñòàðûé 08.09.2003, 11:55
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,934
Ïîáëàãîäàðèëè 33,484 ðàç(à) çà 31,822 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àëåêñåé!
Ïî ïåðâîìó âîïðîñó: âûíóæäåí Âàñ ðàçî÷àðîâàòü - íèêòî íå îöåíèâàåò ÷àñòîòó ÀÀÄ ïðè/ïîñëå ëå÷åíèÿ ÈÏÏÏ: åå îöåíêà ïðîâîäèòñÿ ïîñëå êóðñîâ ðàçëè÷íûõ àíòèáèîòèêîâ. Ñîãëàñíî íåäàâíåìó äîñòóïíî íàïèñàííîìó îáçîðó

Lembcke B, Kist M, Lentze MJ, Bruns J, Gesche M, Herrmann M, Gyr N. Links
Antibiotic-associated diarrhea: incidence, risk factors of antibiotics and patients, pathophysiology and differential diagnosis--an interdisciplinary approach to a common problem.
Schweiz Rundsch Med Prax. 2003 Apr 16;92(16):751-9. Review

åå ÷àñòîòà êîëåáëåòñÿ îò 5% äî 39% è óäåëüíûÉ âåñ â íåé Clostridium difficile-ÀÄ (ÊÄÀÄ) êàê 10-50%. Íàèáîëåå ÷àñòî ÀÀÄ âîçíèêàåò åñëè:
àíòèáèîòèê íàçíà÷àåòñÿ äëèòåëüíî (áîëåå 3-7 äíåé);
ïëîõî âñàñûâàåòñÿ â ÆÊÒ;
ïîäâåðãàåòñÿ ýêñêðåöèè ñ æåë÷üþ;
èìååò àíòèàíàýðîáíîå äåéñòâèå.
Óâåëè÷åíèå ðèñêà ðàçâèòèÿ ïðè ïðèåìå îòä. ÀÁ:
öåôîïåðàçîí (öåôòðèàêñîí) 40%
Àìîêñèêëàâ 10-30%
Ìàêðîëèäû 14%
Àìïèöèëëèí 5-25%
Òåòðàöèêëèí 10-25%
êëèíäàìèöèí 27%
ôòîðõèíîëîíû 17%

Ñðåäè ôàêòîðîâ ðèñêà ïàöèåíòîâ:
âîçðàñò ìëàäøå 6 ëåò, ñòàðøå 65 ëåò
ïàòîëîãèÿ ÆÊÒ
2 è áîëåå ñîïóòñòâóþùèõ çàáîëåâàíèÿ

Òîæå ñàìîå â äð. îáçîðàõ (â îðèãèíàëå)
Bergogne-Berezin E.
Treatment and prevention of antibiotic associated diarrhea.
Int J Antimicrob Agents. 2000 Dec;16(4):521-6. Review.

...Antibiotic associated diarrhea (AAD) is a common complication of antibiotic therapy, occurring in approximately 5 to 25% of patients receiving antibiotics. The incidence of AAD varies with the class of antibiotic used and with risk factors in patients treated: AAD has been observed in a wide variety of patient populations including orthopedic, obstetric/gynecologic, intensive-care-unit patients and even ambulatory patients...

...The incidence of AAD varies between antibiotic classes and, within a given class, significant differences in the impact of a specific molecule on the occurrence of AAD have been underlined. Nearly all antibiotics (except for vancomycin and aminoglycosides) can be responsible for AAD, particularly if the anaerobic intestinal flora form part of their antibacterial spectrum and provided that antibiotic concentrations are high enough in the intestinal lumen to inhibit the anaerobes. The predominant antibiotics that have been reported to produce the highest incidence of AAD are the aminopenicillins (ampicillin/amoxicillin), combination of amoxicillin and clavulanic acid, cephalosporins and clindamycin.


Mylonakis E, Ryan ET, Calderwood SB.
Clostridium difficile--Associated diarrhea: A review.
Arch Intern Med. 2001 Feb 26;161(4):525-33

...Clostridium difficile is the cause of approximately 25% of all cases of antibiotic-associated diarrhea...
...Most cases of C difficile–associated disease occur in hospitals or long-term care facilities (rate of 25-60 per 100 000 occupied bed-days), causing more than 300 000 cases per year in the United States alone. The incidence of this infection in the outpatient setting (7.7 cases per 100 000 person-years; approximately 20 000 cases per year in the United States) is lower, but not negligible. Overall, the risk for development of C difficile–associated diarrhea (CDAD) within 6 weeks of a course of antibiotics in the outpatient setting is low (6.7 cases per 100 000 exposures)...
...Among hospitalized individuals, the risk for CDAD after clindamycin therapy has been estimated to range from 1 in 10 to 1 in 10 000...
... the antibiotics most frequently associated with infection in addition to clindamycin have been ampicillin, amoxicillin, and the cephalosporins...

Íåïëîõèå ñòàò. äàííûå ïðèâåäåíû â â ïðîñïåêòèâí. èññëåäîâàíèè èç Øâåöèè:
Wistrom J, Norrby SR, Myhre EB, Eriksson S, Granstrom G, Lagergren L, Englund G, Nord CE, Svenungsson B.
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study.
J Antimicrob Chemother. 2001 Jan;47(1):43-50.

The frequency of antibiotic-associated diarrhoea (AAD) and Clostridium difficile-associated diarrhoea (CdAD) was prospectively determined in a population of 2462 patients recruited from five Swedish hospitals, including divisions for infectious diseases, orthopaedics, surgery, geriatrics, nephrology and internal medicine. AAD developed in 4.9% of the treated patients...
...and was highest in the nephrology and geriatric units (6.7 and 7.1%, respectively).

Of the 540 subjects with concomitant illness, 6.3% developed AAD. Patients suffering from two or more of these illnesses had a significantly increased risk of AAD (risk ratio 3.01; CI 1.55–5.86; P = 0.001) compared with patients with at most one concomitant disease. No such differences where found among patients with diabetes, chronic renal disease or malignancy only.

A significant increase in risk for AAD was observed for patients treated with antibiotics for >3 days (risk ratio 2.28; CI 1.23–4.21; P = 0.009) (Table IV). No significant differences were found among groups of patients treated for >3 days:

Duration(days) - Number treated - Number (%) with AAD:
less 3 - 422- 10 (2.4)
4–7 - 286 - 15 (5.2)
8–10 - 269 -12 (4.5)
10–21 - 932 - 46 (4.9)

Among groups of patients treated with only one antibiotic, the highest frequencies of AAD (6.7%) were found in patients treated with broad-spectrum penicillins (ampicillin derivatives, pivmecillinam and piperacillin alone or in combination with tazobactam) and those treated with cephalosporins (6.1%). None of those treated only with quinolones or co-trimoxazole developed AAD.
The frequencies of AAD and total illness were also analysed in groups of patients treated with more than one antibiotic either concomitantly or sequentially. The highest frequency of AAD (11%) was observed among those treated with clindamycin in combination with other antibiotics. Among 220 patients treated with metronidazole and 40 treated with glycopeptides in combination with other antibiotics, 7.7 and 5.0%, respectively, developed AAD.
Only one of 80 patients treated solely with cefuroxime experienced symptoms of AAD. When cefuroxime was given in combination with other antibiotics, 4.9% of the patients developed AAD compared with 7.5% for those who received cefotaxime in combinations and 11.4% for patients in whom ceftazidime was the cephalosporin in combinations. The frequency of AAD varied substantially among groups of patients treated with an oral cephalosporin in combination with other antibiotics. The highest frequency of AAD (28.6%, CI 15.9–48.7%) was found in patients treated with cefpodoxime proxetil, as compared with 1.6% in patients given loracarbef.
Tetracycline only: 1 (2.0%); Tetracycline + other: 3 (1.8%).

Äóìàþ, èíôî äëÿ ðàçìûøëåíèÿ ïîêà õâàòèò, ïî-ìîåìó âûáèðàÿ àíòèáèîòèê äëÿ ëå÷åíèÿ ÈÏÏÏ, óæå ìîæíî ïðåäïîëîæèòü âåðîÿòíûé èíäèâèäóàëüíûé ðèñê ÀÀÄ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #53  
Ñòàðûé 08.09.2003, 13:01
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,934
Ïîáëàãîäàðèëè 33,484 ðàç(à) çà 31,822 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûé Àëåêñåé!
Åñëè Âû ñ÷èòàåòå, ÷òî ïî ïåðâîìó ïóíêòó Âàìè ïîëó÷åí óäîâëåòâîðèòåëüíûé îòâåò, òî ïîçâîëüòå ïîïûòàòüñÿ îòâåòèòü íà 2-îé íà îñíîâàíèè äîñòóïíûõ ìíå ìàòåðèàëîâ:
Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J.
Protection from gastrointestinal diseases with the use of probiotics.
Am J Clin Nutr. 2001 Feb;73(2 Suppl):430S-436S. Review.

Diarrhea occurs in less 20% of patients who receive antibiotics. Antibiotic-associated diarrhea (AAD) results from a microbial imbalance that leads to a decrease in the endogenous flora that is usually responsible for colonization resistance and to a decrease in the fermentation capacity of the colon. Clostridium difficile and Klebsiella oxytoca contribute to the occurrence of AAD in some cases and play a role in the pathogenesis of colonic lesions. Several attempts have been made to determine whether the administration of probiotics would prevent antibiotic-associated intestinal symptoms (mainly AAD). Randomized controlled trials that showed a significant therapeutic effect of probiotics are shown in Table 1; the effects of probiotics on C. difficile and K. oxytoca are shown in the next section. Three randomized, double-blind, placebo-controlled studies showed that oral administration of Saccharomyces boulardii (Ultralevure, Biocodex, France) can decrease the risk of AAD (Table). Another study showed that S. boulardii significantly shortened the duration of AAD. The mechanism involved is unclear because multiple biological effects of the yeast in the gastrointestinal tract have been shown, which may contribute to the clinical efficacy of S. boulardii (ie, effects against the population levels of C. difficile, toxins, and intestinal secretion). The therapeutic efficacy of other probiotics is not as well established. It is possible that differences in probiotic preparation may explain why a mixture of freeze-dried lactobacilli significantly prevented diarrhea in 1 study but not in 2 other studies Table). Whether yogurt may help to prevent or cure AAD was suggested in open trials but has not been studied in controlled experiments.

TABLE Randomized controlled trials showing a significant therapeutic effect of probiotics in the prevention of antibiotic-associated intestinal symptoms (mainly diarrhea)

Antibiotic /Probiotic /Blind study /Therapeutic effect1 /(N. of patients)


Ampicillin /Lactobacillus acidophilus + bulgaricus /Yes /8.3% compared with 21% / (n = 98)
Neomycin /L. acidophilus + L. bulgaricus /No /20% compared with 42% / (n = 39)
Amoxicillin-clavulanate /L. acidophilus + L. bulgaricus /No /Positive2 / (n = 27)
Antituberculous /Enterococcus faecium SF68 /No /5% compared with 18% / (n = 200)
Miscellaneous /E. faecium SF68 /Yes /8.7% compared with 27.2% / (n = 45)
Erythromycin /Bifidobacterium longum /Yes /Positive2 / (n = 10)
Erythromycin /Lactobacillus rhamnosus GG /No /Positive2 / (n = 16)
Miscellaneous /L. rhamnosus GG /No /17% compared with 48% / (n = 188)
Clindamycin /B. longum + Lactobacillus /Yes /Positive2 / (n = 10)
ß-lactamins or tetracyclins /Saccharomyces boulardii /Yes /4.5% compared with 17.5% / (n = 388)
Miscellaneous /S. boulardii /Yes /9.5% compared with 21.8% / (n = 180)
ß-lactamins /S. boulardii /Yes 7.2% compared with 14.6% / (n = 193)

1Percentage of subjects with antibiotic-associated intestinal symptoms in the probiotic and control groups, respectively.
2The authors reported a positive effect of the probiotic but did not provide the percentage of subjects with antibiotic-associated adverse effects in the 2 groups.

...Compared with the numerous studies in patients, there have been only a few investigations of otherwise healthy people with or without mild gastrointestinal symptoms, and the often-claimed improvement of well-being by probiotics has not been proven until now.
In a recent controlled, randomized, double-blind study (de Vrese and Schrezenmeir, unpublished observations, 1998), 66 healthy, lactose-tolerant adults in 3 groups—after a 3-wk preperiod without fermented food—consumed 125 g/d of a chemically acidified milk product without bacteria (control) or with 2 strains of probiotic Lactobacillus (1010 CFU/d). Gastrointestinal symptoms and well-being were recorded by validated questionnaires and expressed as a sum score of 5 characteristics concerning intestinal function and pain. Within 1 wk, both probiotics, but not the artificially acidified milk product without bacteria, improved well-being and decreased gastrointestinal symptoms, from 6 to 4 points (on a scale of 0–30 points). These differences were significant (P < 0.05) with respect to both the control subjects and the preperiod without probiotics. This was the first time that such an effect was observed in healthy persons...
Îòâåòèòü ñ öèòèðîâàíèåì
  #54  
Ñòàðûé 08.09.2003, 13:18
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,934
Ïîáëàãîäàðèëè 33,484 ðàç(à) çà 31,822 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïî òðåòüåìó ïóíêòó ê ñîæàëåíèþ êðàéíå ñêóäíî:

èç äîñòóïíûõ èñòî÷íèêîâ èîãóðò ïðèìåíÿëñÿ ÷åðåç ïîë÷àñà ïîñëå ïðèåìà ÀÁ:

Siitonen S, Vapaatalo H, Salminen S, Gordin A, Saxelin M, Wikberg R, Kirkkola AL.
Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea.
Ann Med. 1990 Feb;22(1):57-9.

äâàæäû â äåíü (ó.â.) ïî 125 ìë â ñîñòàâå Lb. GG áåç óêàçàíèÿ êîíöåíòðàöèè ìèêðîîðãàíèçìîâ;

èëè

supplement of Lactobacillus- and Bifidobacterium-containing yogurt (AB-Yogurt, President Corp., Tainan, Taiwan) (triple-plus-yogurt group) and those receiving 1-week triple therapy without the supplement (triple-only group). In the triple-plus-yogurt group, the regimen of 1-week triple therapy consisted of lansoprazole (30 mg) (before breakfast and dinner), amoxicillin (1 g) (half an hour after breakfast and dinner) and clarithromycin (500 mg) (half an hour after breakfast and dinner) twice daily. Half an hour after the antibiotics, 200 mL AB-Yogurt (containing at least 5 õ 109 live organisms per bottle) was taken twice daily. The supplement of 200 mL AB-Yogurt was continued for 4 weeks after triple therapy in the triple-plus-yogurt group.
Sheu BS, Wu JJ, Lo CY, Wu HW, Chen JH, Lin YS, Lin MD. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.
Aliment Pharmacol Ther. 2002 Sep;16(9):1669-75.

Âíÿòíûõ îáüÿñíåíèé ïî÷åìó òàêèå äîçèðîâêè èëè âðåìåííûå ïðîìåæóòêè íàéòè íå óäàëîñü.
Îòâåòèòü ñ öèòèðîâàíèåì
  #55  
Ñòàðûé 08.09.2003, 13:36
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,934
Ïîáëàãîäàðèëè 33,484 ðàç(à) çà 31,822 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íàòêíóëñÿ íà îäíó ñòàòåéêó, ìîæåò êàê-òî ïðîêîììåíòèðóåòå:

General Practice In Action
"Not thrush again!" Women's experience of post-antibiotic vulvovaginitis
Marie V Pirotta, Jane M Gunn and Patty Chondros
MedJournAustral 2003; 179 (1): 43-46

Objectives: To examine the frequency of post-antibiotic vulvovaginitis (PAV); describe how women prevent and treat PAV; and determine whether concern about PAV affects their decisions about taking antibiotics.
Design: Cross-sectional survey using a written questionnaire.
Setting and participants: Five general practice waiting rooms in north-western Melbourne, in February 2000. 1298 women aged 18–70 years were surveyed.
Main outcome measures: Self-reported symptoms and management of vulvovaginitis and PAV.
Results: The response rate was 86%. Thirty-five per cent of women reported ever having PAV and 73% reported ever having symptoms suggestive of vulvovaginal candidiasis. Antifungal medications and lactobacillus products or yoghurt were most popular for both prevention (49%, 40%) and treatment (63%, 43%) of PAV.

Health advice

Consult doctor 419/750 (55.9%) prevention

Consult GP 488/711 (68.6%) treatment

Consult gynaecologist 82/693 (11.8%) treatment

Consult complementary therapist 54/748 (7.2%) prevention

...As in the US studies, about 40% of the women used yoghurt or lactobacillus products to prevent or treat PAV. Women in our sample preferred the oral route; however, at the time of our survey there were no convenient per-vaginum forms of these therapies commercially available. Despite the popularity among women of complementary and alternative products for this indication, there is no evidence that any of these treatments are effective. The limited research in this area has shown promising but inconclusive results for the effectiveness of lactobacillus in treating recurrent vulvovaginal candidiasis...

Ýòî ÿ ê òîìó, ÷òî íå òîëüêî íåòðàäèöèîííûå äîêòîðà ñîâåòóþò ïðîáèîòèêè/èîãóðòû...
Îòâåòèòü ñ öèòèðîâàíèåì
  #56  
Ñòàðûé 08.09.2003, 14:23
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,934
Ïîáëàãîäàðèëè 33,484 ðàç(à) çà 31,822 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
"Òîëüêî ïðî ôàðììàôèþ íå íàäî. Íàäåþñü Âû íå ðàçäåëÿåòå ýòè ïàðàíîÿëüíûå èäåè, ÷òî îíà äå óïðàâëÿåò àìåðèêàíñêîé ìåäèöèíîé."

 òåìó ëèøü îäèí ïðèìåð î òîì ïî÷åìó è êàê òåñòèðóþòñÿ ìåäèêàìåíòû è ïðîâîäÿòñÿ òðàéëû:

Ïîëîæèòåëüíûé ýôôåêò ïåíòîêñèôèëëèíà ïðè èäèîïàòè÷åñêîé ÕÑÍ áûë çàìå÷åí â êîíöå 80 - íà÷àëå 90 è ýòîò ýôôåêò ïîòåíöèàëüíî îáüÿñíÿëñÿ èç-çà ñíèæåíèÿ ïîâûøåííîãî ÔÍÎ.

Nordhus O, Ekestrom S, Liljeqvist L.
Effects of pentoxifylline on central hemodynamics in patients with congestive heart failure.
Scand J Thorac Cardiovasc Surg. 1986;20(3):217-20.
Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P.
Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.
Lancet. 1998 Apr 11;351(9109):1091-3.


Îäíàêî â êîíöå 90-õ áûëè îðãàíèçîâàíû êðóïíûå òðàéëû RENAISSANCE, RECOVER, RENEWAL with etanercept (2048 patients), à òàêæå ATTACH (150) with infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha
è âñå îáëîæàëèñü. Ðåçóëüòàò îêàçàëñÿ ñëåäóþùèì:

On 22nd March, 2001, Immunex' stock closed at US$18.88 after more than 29 million shares had changed hands. For this major biotech company, this was the largest number of shares traded in a single day in its nearly 10 years of existence. The next day, the stock opened at US$ 10.88, and after more than 93 million shares had been traded the stock closed at $ 11.63 – a loss of 38% (or more than US$ 4 billion) within 24 hours.
What had happened? Two trials testing an anti-cytokine medication in chronic heart failure (CHF) had been halted. Observing an estimate of the effect of etanercept (Enbrel®, which can reduce bioactivity of tumor necrosis factor alpha [TNF]) on the morbidity/mortality endpoint that was unfavourable, the Independent Data Safety Monitoring Board (DSMB) recommended early termination of the two trials; RENAISSANCE and RECOVER (and in effect also of the combined analysis (coined RENEWAL). When the news hit Wall Street, the stock price plummeted.

Èç - Anker SD, Coats AJ.
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.
Int J Cardiol. 2002 Dec;86(2-3):123-30.

Íå áóäåì âäàâàòüñÿ âî ñêîëüêî "âñòàëè" ýòè òðàéëû ôèðìàì, íî î òðàéëàõ ñ ïåíòîêñèôèëëèíîì, êîòîðûé óæå ïîõîæå òîëüêî ëåíèâàÿ ôàðìêîìïàíèÿ íå ïðîèçâîäèò - òèøèíà, õîòÿ ýíòóçèàñòû ïðîäîëæàþò ïîêàçûâàòü íà ñðåäñòâà êëèíèêè/ôîíäîâ åãî ïîëîæèòåëüíûé ýôôåêò:

Sliwa K, Woodiwiss A, Candy G, Badenhorst D, Libhaber C, Norton G, Skudicky D, Sareli P.
Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Am J Cardiol. 2002 Nov 15;90(10):1118-22.

Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P.
Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
Circulation. 2001 Feb 27;103(8):1083-8.

È ýòî íå åäèíè÷íûå ïðèìåðû â ìåäèöèíå...
Îòâåòèòü ñ öèòèðîâàíèåì
  #57  
Ñòàðûé 09.09.2003, 07:07
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
mina òóò ïðîáëåìà ÿâíî íå â óðåàïëàçìàõ. Ýòî ëèáî ëàáîðàòîðèÿ âðåò, ëèáî âðà÷è ãîëîâó äóðÿò, ëèáî âû ïîâòîðíî çàðàæàåòåñü (îò íåëå÷åííîãî ïàðòíåðà èëè ó Âàñ èõ íåñêîëüêî), ëèáî ïðè÷èíà âîñïàëåíèÿ â äðóãîé èíôåêöèè. Äðóãèõ ïðîáëåì ñ óðåàïëàçìàìè ìèð íå çíàåò. Ìîæåò Ðîñòîâ-íà-Äîíó èñêëþ÷åíèå?
Îòâåòèòü ñ öèòèðîâàíèåì
  #58  
Ñòàðûé 16.09.2003, 21:01
Tashaia Tashaia âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 07.09.2003
Ãîðîä: Rostov
Ñîîáùåíèé: 3
Tashaia *
Îòâåò äëÿ Ìèíû: ïîëèêëèíèêà íà ×åõîâà....
Îäíàêî íå ðåêîìåíäóþ ò.ê.:
1) î÷ áîëüøèå ñîìíåíèÿ íà ñ÷åò äîñòîâåðíîñòè àíàëèçà, ñóäÿ ïî ñïîñîáó âçÿòèÿ è ñðîêó ãîòîâíîñòè- 10 äíåé - áûëî ïîõîæå íà áàê.ïîñåâ, íî íà áóìàæå÷êå ïî÷åìó-òî ÏÖÐ....
2)àíàëèçû ïîëíîñòüþ ïðîõîäèëè ÷åðåç âðà÷à, â ò.÷. îïëàòà.
3)ïî ýíöèêëîïåäèè ëåê.ïðåïàðàòîâ èçó÷èëà ïîêàçàíèÿ íà âåñü êóðñ...., ìîæåò áûòü ÿ íåïðàâà íî òàêîå îùóùåíèå, ÷òî ìåíÿ âðà÷ ðåøèëà âûëè÷èòü îò âñåãî è ñðàçó.
Ãåðîéñòâîì è ñàìîïîæåðòâîâàíèåì íèêîãäà íå îòëè÷àëàñü, ïîýòîìó äóìàþ êóäà ïîäàòüñÿ è ïîäàâàòüñÿ ëè âîîáùå, ò.ê. ó ìåíÿ êàê â àíåêäîòå: "íå ÷èøèòå, ñàì ïðîéäåò.."
Äîêòîðà, ïîñîâåòóéòå, ïëç, êàê èçáåæàòü øàðëàòàíñòâà è äåíãîâûóæèâàíèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #59  
Ñòàðûé 16.09.2003, 22:35
Zhivov Zhivov âíå ôîðóìà
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 20.08.2001
Ñîîáùåíèé: 3,792
Zhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåZhivov ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
êàê èçáåæàòü øàðëàòàíñòâà è äåíãîâûóæèâàíèÿ?

Ñïîñîá òîëüêî îäèí. Ïðåæäå ÷åì îáðàòèòüñÿ â êàêîå-ëèáî ëå÷åáíîå ó÷ðåæäåíèå èëè ê êàêîìó-ëèáî âðà÷ó, ïîñòàðàéòåñü ïîëó÷èòü î íèõ êàê ìîæíî áîëüøå èíôîðìàöèè îò çíàêîìûõ âàì ëþäåé, îöåíèòå èõ ðåïóòàöèþ. Åñëè âàì ïðåäëàãàþò â îäíè ðóêè çàïëàòèòü è çà àíàëèçû, è çà ëåêàðñòâà, è âîîáùå çà âñå - îñòåðåãàéòåñü ïîääåëîê âî âñåõ ñìûñëàõ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #60  
Ñòàðûé 17.09.2003, 17:58
Tashaia Tashaia âíå ôîðóìà
Ñåðôåð
 
Ðåãèñòðàöèÿ: 07.09.2003
Ãîðîä: Rostov
Ñîîáùåíèé: 3
Tashaia *
Ñåãîäíÿ íàêîíåö-òî ïîëó÷èëà äîêóìåíò ïî ñâîèì àíàëèçàì: íàïðîòèâ Ureaplasma urealiticum ìåòî÷êà "ïîëîæ (#)",
ïî îñòàëüíûì (ïîðÿäêà 8 íàèìåíîâàíèé) - "íåïð".Ñêàçàëè, ÷òî èññëåäîâàíèÿ ïðîâîäÿòñÿ â Ðîñòîâñêîì ïðîòèâî÷óìíîì,
õîòÿ øòàìïà è íàèìåíîâàíèÿ ñåãî íà äîêóìåíòå íå ïðèñóòñòâóåò, òîëüêî ïîäïèñü Âðà÷, äîê.ìåä íàóê Âîäîïüÿíîâ Ñ.Î.
Âîò òàêèå ïèðîãè....
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 16:57.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.